Gender plays an important role in the incidence, progression and prognosis of individuals with several forms of hematological malignancy. In the context of B-cell lymphoproliferative disorders, there is a marked preponderance of men (4:1 male to female ratio) in diseases such as hairy cell leukemia. 1 For chronic lymphocytic leukemia (CLL), data derived from both national registries and from prospective clinical trials have shown an increased incidence of men (reviewed in Molica 2 ). One registry study reported a fivefold excess of men in patients presenting at about 40 years of age. 3 Men tend to present with more clinically advanced disease and have a worse prognosis. Randomized clinical trials have shown that even allowing for clinical stage, men have a worse prognosis than women. The biological basis for these differences remains unclear; possible explanations include molecular, genetic and hormonal differences.
Studies on the expression of the immunoglobulin (IG) V region gene segments in CLL have revealed a number of biologically and clinically interesting points. First, there are two subsets of CLL that can be defined by the presence or absence of somatic mutations. Presence of somatic mutations is associated with a better prognosis. In one previous study, there was a 2:1 male excess in CLL patients with unmutated disease, whereas the mutated CLL showed male to female equivalence. 4 Second, several studies have shown highly restricted IG rearrangements in CLL, both in terms of IGHV gene segment usage and in terms of antigen-binding sequences, suggesting a strong role for antigen selection during the development of the disease. 5 A number of the 'stereotypical' IG receptors involve the IGHV1-69 gene segments. IGHV1-69 gene segment usage is found in about 10-15% of all CLL patients. In most instances, these segments remain unmutated. Sequence analysis of both heavy-and light-chain gene sequences has shown strong conservation of the antigen-binding site.
We have studied the frequency and nature of IGHV rearrangements in CLL patients from three separate databases; first, from the Leukemia Research CLL4 trial (containing only patients requiring therapy), and second, from two comprehensive databases from Bournemouth and Leicester in the United Kingdom, representing unselected patients seen in both clinics. We report that uniquely, IGHV1-69 gene segment usage occurs predominantly in men. No other significant gender differences were consistently detected in any other common IGHV subgroup.
Blood samples were taken from patients with CLL following informed, written consent and with local ethical committee approval. Genomic DNA and total cellular RNA were isolated using Qiagen columns (Hilden, Germany) from leukemic mononuclear cells prepared by centrifugation on a Ficoll gradient. Amplification and sequence analysis of IGH rearrangements by DNA PCR according to BIOMED-2 protocols or reverse transcription-PCR (RT-PCR) was performed, as described previously. Although sequence data were analyzed on at least two databases (IMGT, IgBlast, V-BASE), results were reported using the IMGT database (http://imgt.cines.fr). Sequences with a germline homology of 98% or higher were considered as unmutated, and those with a homology less than 98% were considered as mutated. IGVH mutational data were collected from a total of 1239 patients, comprising 540 patients entered into the CLL4 clinical trial, 392 patients attending the Royal Bournemouth Hospital and 307 patients, Leicester Royal Infirmary. The latter two cohorts represent unselected datasets of consecutive patients attending either hospital. The IGHV segment usage in the three different cohorts was broadly similar, although there was over-representation of IGHV1-69 in the CLL4 cohort and possible under-representation of IGHV3-21 in the Bournemouth database; IGHV4-34 was also under-represented in the CLL4 series. We assessed the male to female ratio in each cohort according to IGHV segment usage. Overall, the male to female ratio in all three cohorts was 2.1:1. Data from the eight most commonly utilized IGHV gene segments according to gender are shown in Figure 1 . In all three cohorts, the IGHV1-69 subset contained an excess of men. Overall, there were 133 men and 28 women utilizing IGHV1-69 (ratio 4.75:1); comparison of this ratio with the overall ratio within the CLL population showed that this was highly significant (Pvalue ¼ 0.000002 using parametric one-sample proportion test). Similar gender imbalances were not seen in any other of the other commonly utilized IGHV subgroups. Within the IGHV1-69 group, there were no significant gender imbalances seen within the described stereotypical subsets of sequences. 6 Eight of the 92 patients with IGHV1-69 usage entered into the CLL4 study were mutated. In the Leicester series, there were five out of 28 cases with more than 2% mutations; none of these were women. All mutated IGHV1-69 cases presented with Binet stage A(0) disease and only one has required treatment to date; the lymphocyte doubling time was much slower in mutated IGHV1-69 cases as shown in Figure 2 . In terms of rate of accumulation of lymphocytes in the peripheral blood, there was a significant difference between mutated and unmutated IGHV1-69 (P ¼ 0.002, Student's t-test, Figure 2c ). Interestingly, while most of the IGHV1-69 cases required therapy early in the course of their disease, some unmutated IGHV1-69 cases exhibited long periods where the disease was only slowly progressive ( Figure 2) . In one instance, more rapidly progressive disease was associated with a secondary 11q23 chromosomal deletion by FISH (data not shown). Together, these data indicate that the difference between mutated and unmutated IGHV1-69 subgroups may be the rate of acquisition of deleterious secondary genetic events that drive accelerated proliferation.
One other rarer IGHV subgroup may also show comparable male imbalance; from the CLL4 study, IGHV1-18 was observed in 14 men compared with only one woman. However, this gene segment was only utilized in six other patients within the other two cohorts, which did not permit statistical analysis.
The association of IGHV1-69 gene segment usage in CLL and male gender is intriguing. The stereotypical nature of the IGHVDJ rearrangements in CLL, and particularly in subsets such as those utilizing IGHV1-69, suggests that the same antigen(s) or epitopes are involved in the early stages of the pathogenesis of the disease. IGHV1-69 antibodies are polyreactive but may also bind to apoptotic Jurkat cells. 7 The association of male gender with IGHV1-69 would indicate that the possible autoantigen would be encoded on the sex chromosomes.
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